These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8461270)

  • 1. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YW; Jann MW
    Schizophr Res; 1993 Mar; 9(1):35-40. PubMed ID: 8461270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
    Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
    Gelders YG
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen.
    Ereshefsky L; Saklad SR; Tran-Johnson T; Toney G; Lyman RC; Davis CM
    Psychopharmacol Bull; 1990; 26(1):108-14. PubMed ID: 2371365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 12-month study of haloperidol decanoate in chronic schizophrenic patients.
    Gelders YG; Reyntijens AJ; Ash CW; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):247-54. PubMed ID: 7185769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
    Glick ID; Marder SR
    J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
    Eberhard G; Hellbom E
    Acta Psychiatr Scand; 1986 Sep; 74(3):255-62. PubMed ID: 3788652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of haloperidol decanoate on the cardiovascular system.
    Kaneko S; Edwards JG; Goldie A; Fukushima Y; Sato T
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):73-7. PubMed ID: 1684394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
    Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A loading-dose strategy for converting from oral to depot haloperidol.
    Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D
    Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate.
    Jann MW; Wei FC; Lin HN; Piao-Chien C; Chang WH
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jan; 20(1):73-86. PubMed ID: 8861178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.